IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i1p574-d717985.html
   My bibliography  Save this article

Integrated Genomic and Bioinformatics Approaches to Identify Molecular Links between Endocrine Disruptors and Adverse Outcomes

Author

Listed:
  • Jacopo Umberto Verga

    (Dipartimento di Scienze della Vita e dell’Ambiente, Università Politecnica delle Marche, 60131 Ancona, Italy
    School of Biological Sciences, Institute for Global Food Security, Queens University Belfast, Belfast BT9 5DL, UK
    These authors contributed equally to this work.
    Current address: The SFI Centre for Research Training in Genomics Data Science, National University of Ireland, H91 FYH2 Galway, Ireland.)

  • Matthew Huff

    (Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA
    These authors contributed equally to this work.
    Current Address: Department of Entomology and Plant Pathology, University of Tennessee, Knoxville, TN 37996, USA.)

  • Diarmuid Owens

    (School of Biological Sciences, Institute for Global Food Security, Queens University Belfast, Belfast BT9 5DL, UK)

  • Bethany J. Wolf

    (Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC 29425, USA)

  • Gary Hardiman

    (School of Biological Sciences, Institute for Global Food Security, Queens University Belfast, Belfast BT9 5DL, UK
    Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA)

Abstract

Exposure to Endocrine Disrupting Chemicals (EDC) has been linked with several adverse outcomes. In this review, we examine EDCs that are pervasive in the environment and are of concern in the context of human, animal, and environmental health. We explore the consequences of EDC exposure on aquatic life, terrestrial animals, and humans. We focus on the exploitation of genomics technologies and in particular whole transcriptome sequencing. Genome-wide analyses using RNAseq provides snap shots of cellular, tissue and whole organism transcriptomes under normal physiological and EDC perturbed conditions. A global view of gene expression provides highly valuable information as it uncovers gene families or more specifically, pathways that are affected by EDC exposures, but also reveals those that are unaffected. Hypotheses about genes with unknown functions can also be formed by comparison of their expression levels with genes of known function. Risk assessment strategies leveraging genomic technologies and the development of toxicology databases are explored. Finally, we review how the Adverse Outcome Pathway (AOP) has exploited this high throughput data to provide a framework for toxicology studies.

Suggested Citation

  • Jacopo Umberto Verga & Matthew Huff & Diarmuid Owens & Bethany J. Wolf & Gary Hardiman, 2022. "Integrated Genomic and Bioinformatics Approaches to Identify Molecular Links between Endocrine Disruptors and Adverse Outcomes," IJERPH, MDPI, vol. 19(1), pages 1-24, January.
  • Handle: RePEc:gam:jijerp:v:19:y:2022:i:1:p:574-:d:717985
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/1/574/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/19/1/574/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
    2. Sophie Depiereux & Florence Le Gac & Bertrand De Meulder & Michael Pierre & Raphaël Helaers & Yann Guiguen & Patrick Kestemont & Eric Depiereux, 2015. "Meta-Analysis of Microarray Data of Rainbow Trout Fry Gonad Differentiation Modulated by Ethynylestradiol," PLOS ONE, Public Library of Science, vol. 10(9), pages 1-27, September.
    3. Chao Chen & Kay Grennan & Judith Badner & Dandan Zhang & Elliot Gershon & Li Jin & Chunyu Liu, 2011. "Removing Batch Effects in Analysis of Expression Microarray Data: An Evaluation of Six Batch Adjustment Methods," PLOS ONE, Public Library of Science, vol. 6(2), pages 1-10, February.
    4. Siew Hong Lam & Sinnakarupan Mathavan & Yan Tong & Haixia Li & R Krishna Murthy Karuturi & Yilian Wu & Vinsensius B Vega & Edison T Liu & Zhiyuan Gong, 2008. "Zebrafish Whole-Adult-Organism Chemogenomics for Large-Scale Predictive and Discovery Chemical Biology," PLOS Genetics, Public Library of Science, vol. 4(7), pages 1-14, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.
    2. Yusuke Oh & Koji Takahashi, 2020. "R&D and Innovation: Evidence from Patent Data," Bank of Japan Working Paper Series 20-E-7, Bank of Japan.
    3. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
    4. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
    5. Unsal, Omer & Houston, Reza, 2024. "R&D grants and medical innovation," Journal of Economics and Business, Elsevier, vol. 128(C).
    6. Alfred B. Ordman, 2022. "When Will the FDA Do What Is in People’s Best Interests?," American Journal of Economics and Sociology, Wiley Blackwell, vol. 81(4), pages 721-751, September.
    7. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.
    8. Xia Qing & Thompson Jeffrey A. & Koestler Devin C., 2021. "Batch effect reduction of microarray data with dependent samples using an empirical Bayes approach (BRIDGE)," Statistical Applications in Genetics and Molecular Biology, De Gruyter, vol. 20(4-6), pages 101-119, December.
    9. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    10. Fabian Gaessler & Stefan Wagner, 2022. "Patents, Data Exclusivity, and the Development of New Drugs," The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
    11. Gregor Dorfleitner & Felix Rößle, 2018. "The financial performance of the health care industry: a global, regional and industry specific empirical investigation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 585-594, May.
    12. Farasat A. S. Bokhari & Franco Mariuzzo & Anna Rita Bennato, 2021. "Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions," Small Business Economics, Springer, vol. 57(1), pages 603-634, June.
    13. Stig Johan Wiklund, 2019. "A modelling framework for improved design and decision-making in drug development," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-22, August.
    14. Yin, Nina, 2023. "Pharmaceuticals, incremental innovation and market exclusivity," International Journal of Industrial Organization, Elsevier, vol. 87(C).
    15. Rathi, Sawan & Majumdar, Adrija & Chatterjee, Chirantan, 2024. "Did the COVID-19 pandemic propel usage of AI in pharmaceutical innovation? New evidence from patenting data," Technological Forecasting and Social Change, Elsevier, vol. 198(C).
    16. Heyoung Yang & Hyuck Jai Lee, 2018. "Long-Term Collaboration Network Based on ClinicalTrials.gov Database in the Pharmaceutical Industry," Sustainability, MDPI, vol. 10(2), pages 1-14, January.
    17. Ralph Siebert & Zhili Tian, 2020. "Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry," CESifo Working Paper Series 8303, CESifo.
    18. Stacy Sneeringer & Matt Clancy, 2020. "Incentivizing New Veterinary Pharmaceutical Products to Combat Antibiotic Resistance," Applied Economic Perspectives and Policy, John Wiley & Sons, vol. 42(4), pages 653-673, December.
    19. Gemma Turon & Jason Hlozek & John G. Woodland & Ankur Kumar & Kelly Chibale & Miquel Duran-Frigola, 2023. "First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    20. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing 001842, Office of Health Economics.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:1:p:574-:d:717985. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.